![Despite Headwinds, Biosimilars Market Is Growing in 2024](https://getmga.com/wp-content/uploads/2024/07/iStock-1272520901-1080x675.jpg)
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
“A big responsibility is falling on the IRS to deal with this problem, when, in fact, Congress could be dealing with this problem,” Brill said.”
On May 13, experts convened at AEI to discuss the United States’ fiscal trajectory: how we got here, where we’re going, and what we can do to reduce the burden of debt for future generations.
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.